Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGAV | P06756 | 1/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.52 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 4/20 | 0.51 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | KLK2 | P20151 | 1/20 | 0.49 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.49 |
| ▸ | KLK13 | Q9UKR3 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24218675 | 0.94 | KLKB1 (0.59) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218598 | 0.93 | KLKB1 (0.59) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218595 | 0.93 | KLKB1 (0.59) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218652 | 0.92 | KLKB1 (0.57) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218671 | 0.92 | KLKB1 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218673 | 0.92 | KLKB1 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218668 | 0.89 | KLKB1 (0.53) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218677 | 0.87 | ITGB3 (0.56) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218590 | 0.86 | KLKB1 (0.57) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24218599 | 0.86 | KLKB1 (0.52) | ITGB3ITGB1ITGAVITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | ITGB3 4848/4885ITGB1 4867/4885ITGAV 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.